L. Montejano

发表

Impact of access restrictions on varenicline utilization

K. Zou, G. Lenhart, A. Galaznik, 2013, Expert review of pharmacoeconomics & outcomes research.

Impact of Out-of-pocket Costs on Varenicline Utilization and Persistence

K. Zou, G. Lenhart, A. Galaznik, 2014 .

Development and validation of a claims-based approach to proxy ECOG performance status across ten tumor groups.

A. Davidoff, L. Bowman, K. Sheffield, 2018, Journal of comparative effectiveness research.

Healthcare costs associated with switching from brand to generic levothyroxine.

J. Scherger, Stella Chang, S. Conard, 2010, American health & drug benefits.

Medication-assisted treatment with buprenorphine: assessing the evidence.

C. Thomas, Meelee Kim, L. Montejano, 2014, Psychiatric services.

Cost of illness and comorbidities in adults diagnosed with attention-deficit/hyperactivity disorder: a retrospective analysis.

D. Huse, P. Hodgkins, L. Montejano, 2011, The primary care companion for CNS disorders.

Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States

E. Riehle, G. Lenhart, R. White, 2018, Journal of managed care & specialty pharmacy.

Medication-Assisted Treatment With Buprenorphine: Assessing the Evidence

C. Thomas, Meelee Kim, L. Montejano, 2015 .

Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon‐like peptide‐1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once‐weekly exenatide and liraglutide

C. Alatorre, R. Swindle, P. Juneau, 2017, Diabetes, obesity & metabolism.

Medication-assisted treatment with methadone: assessing the evidence.

C. Thomas, Meelee Kim, L. Montejano, 2014, Psychiatric services.

Factors affecting detoxification readmission: analysis of public sector data from three states.

T. Mark, L. Montejano, Rita Vandivort-Warren, 2006, Journal of substance abuse treatment.

Risk of injury associated with attention-deficit/hyperactivity disorder in adults enrolled in employer-sponsored health plans: a retrospective analysis.

D. Huse, P. Hodgkins, L. Montejano, 2011, The primary care companion for CNS disorders.

Medication-AssistedTreatmentWith Methadone:AssessingtheEvidence

Meelee Kim, L. Montejano, Allen S. Daniels, 2014 .

Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder

L. Montejano, N. Ronquest, T. Willson, 2018, Substance abuse and rehabilitation.

Comparison of healthcare utilization among patients treated with alcoholism medications.

T. Mark, H. Kranzler, D. Gastfriend, 2010, The American journal of managed care.

Transitions of Care for People with Type 2 Diabetes: Utilization of Antihyperglycemic Agents Pre- and Post-Hospitalization

L. Vo, L. Montejano, D. Mcmorrow, 2015, Diabetes Therapy.

Impact of Bipolar Disorder on Employers

R. Goetzel, R. Ozminkowski, L. Montejano, 2005 .

Costs and Resource Utilization Among Medicaid Patients with Schizophrenia Treated with Paliperidone Palmitate or Oral Atypical Antipsychotics

David M. Smith, E. Muser, J. Pesa, 2015, Drugs - Real World Outcomes.

The relationship between Eastern Cooperative Oncology Group performance status and healthcare resource utilization among patients with advanced or metastatic colorectal, lung or gastric cancer

W. Schelman, A. Liepa, L. Bowman, 2020, Journal of drug assessment.

Dose trends for second-generation antipsychotic treatment of schizophrenia and bipolar disorder

L. Citrome, L. Palmer, C. Reist, 2009, Schizophrenia Research.

Healthcare Costs Associated with Osteoarthritis in US Patients

T. Le, D. Ang, L. Montejano, 2012, Pain practice : the official journal of World Institute of Pain.

Characteristics and treatment patterns of US commercially insured and Medicaid patients with opioid dependence or abuse.

L. Montejano, N. Ronquest, T. Willson, 2017, Journal of opioid management.

Health care costs in US patients with and without a diagnosis of osteoarthritis

T. Le, D. Ang, L. Montejano, 2012, Journal of pain research.

Impact of real-world ziprasidone dosing on treatment discontinuation rates in patients with schizophrenia or bipolar disorder

L. Citrome, L. Palmer, C. Reist, 2009, Schizophrenia Research.

Adult ADHD: prevalence of diagnosis in a US population with employer health insurance

D. Huse, P. Hodgkins, L. Montejano, 2011, Current medical research and opinion.

Persistence with oral naltrexone for alcohol treatment: implications for health-care utilization.

J. Stephenson, H. Kranzler, D. Gastfriend, 2008, Addiction.

Real‐World Dosing Patterns of Atomoxetine in Adults with Attention‐Deficit/Hyperactivity Disorder

C. Alatorre, A. Farr, L. Montejano, 2015, CNS neuroscience & therapeutics.

Effects of naltrexone treatment for alcohol-related disorders on healthcare costs in an insured population.

J. Stephenson, H. Kranzler, D. Gastfriend, 2010, Alcoholism, clinical and experimental research.

Healthcare costs of urinary tract infections and genital mycotic infections among patients with type 2 diabetes mellitus initiated on canagliflozin: a retrospective cohort study

S. Bolge, P. Juneau, L. Montejano, 2017, Journal of medical economics.

How to Measure ‘Opioid Relapse’ in Real-World Claims Data

A. Cole, L. Montejano, N. Ronquest, 2016 .